Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.

March 14, 2025

Vol.51 No.10

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Podcast

In The Headlines: Kimryn Rathmell on loss and caring for our community in uncertain times

In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.

February 19, 2025

Vol.51 No.06

Guest Editorial

Preparing to take care of each other in ways we never imagined

Being summarily dismissed, denigrated, and divided is both dehumanizing and taking place in a radical and disorienting manner. The effect is traumatizing.

February 14, 2025

Vol.51 No.06

By W. Kimryn Rathmell

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

Brief cognitive behavioral therapy appears promising for head and neck cancer survivors with body-image distress

YOU MAY BE INTERESTED IN

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

In The Headlines: Kimryn Rathmell on loss and caring for our community in uncertain times

Preparing to take care of each other in ways we never imagined

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login